Swedish medical devices company Molnlycke Health Care has announced the launch of its Avance Solo, a true negative pressure wound therapy (NPWT) system, in the UK.
Medela, Molnlycke Health Care's collaboration partner within NPWT, has designed the Avance Solo system that has variable pressure settings.
This single patient-use portable system which weighs 400g and can easily be carried or worn in a discreet manner provides benefits to both patients and health care providers.
Avance Solo, which is designed to be used together with Molnlycke Health Care's Avance Film with Safetac technology, Mepiseal and Mepitel wound contact layer, will help reduce unnecessary patient suffering during dressing changes.
Molnlycke Health Care NPWT global business director Steve Atlay noted complementing the company's existing NPWT offering with a single patient-use system demonstrates its innovation capabilities in a global market estimated to be worth over €1bn.
"Following a successful launch in the UK, we are also targeting launches across other selected markets during 2014.
"By combining our Safetac Technology with an easy-to use and portable system, patients now have access to true negative pressure therapy in their home and on the go, without having to experience the unnecessary pain and suffering otherwise associated with this form of treatment," Atlay added.
